Loading...
Lorazepam — Export Intelligence Report
2025-Q4 · TransData Nexus
PHARMA TRADE INTELLIGENCE
INDIA EXPORT INTELLIGENCE REPORT
Lorazepam
2025-Q4
Comprehensive analysis of India’s lorazepam export trade — suppliers, buyers, prices, routes, and every shipment record.
24
Shipments
$363K
Trade Value
10
Suppliers
10
Buyers
10
Countries
Scan for online report
Talk to our analyst: +91 95950 78788
https://transdatanexus.com/pharmaceutical/lorazepam
01
PART I — OVERVIEW
Executive Summary
At-a-glance KPIs, key findings, and strategic positioning of India’s lorazepam trade — 2025-Q4
KEY TAKEAWAY
Lorazepam 2025-Q4 exports total $363.3K across 10 countries, with ESJAY PHARMA PVT LTD commanding 55.7% market share.
TOTAL SHIPMENTS
24
2025-Q4
EXPORT VALUE
$363.3K
FOB USD
TOTAL QUANTITY
3.0M
units shipped
INDIAN SUPPLIERS
10
unique exporters
GLOBAL BUYERS
10
unique importers
DESTINATIONS
10
countries
MEDIAN UNIT PRICE
$0.700
per unit
TOP-5 SHARE
89.4%
of total USD
BRANDED SHARE
58.3%
14 shipments
DOSAGE FORMS
3
product types
6 KEY FINDINGS
1
ESJAY PHARMA PVT LTD is India's #1 Lorazepam exporter with $202.3K (55.7% market share).→ §5, Indian Supplier Rankings
2
Lorazepam reached 10 countries, with United States as the top destination ($202.3K).→ §4, Global Destination Map
3
Market concentration is high (HHI: 3432) — top 10 suppliers control 100.0% of exports.→ §5, Indian Supplier Rankings
4
100.0% of buyers (10 of 10) source from a single Indian supplier — potential poaching opportunities.→ §6, Global Buyer Rankings
5
Tablet dominates (88.1%) across 3 dosage forms.→ §7, Price Benchmarks
6
10 countries have ≤5 Indian suppliers — easy-entry markets for SME exporters.→ §9, Strategic Opportunities
WHO THIS REPORT IS FOR
S SUPPLIERS (Indian pharma exporters)
- See which buyers your competitors are shipping to, at what price, through which ports
- Identify buyers that are single-sourced (poaching opportunities)
- Benchmark your pricing and catalog vs the Top 25
B BUYERS (global importers)
- Discover which Indian exporters supply this product and what they sell
- Benchmark the price you are paying vs the market median by country and dosage
- Identify alternative suppliers with proven exports to similar destinations
Figure 1.1 ESJAY PHARMA PVT LTD leads in volume — how do 10 exporters compare on price × volume?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Every bubble is one Indian lorazepam exporter. X-axis = shipment count; Y-axis = average unit price; bubble size = total revenue. Dashed lines split at the median — exporters in the top-right (Bulk Leaders) combine high volume with premium pricing.
HOW TO READ THIS REPORT
60 seconds
Scan this page — KPIs, thesis, flagship chart, top findings
5 minutes
Read every Key Takeaway line across §1–§9
30 minutes
Read sections tagged for your role ([S] or [B]) end-to-end
In depth
Drill into §10 for your country · supplier / buyer directories at end
02
PART I — OVERVIEW
About This Report
Data sources, methodology, trust signals, and what this Lorazepam report covers
KEY TAKEAWAY
Every figure in this report is grounded in real commercial lorazepam trade records. Data comes from official customs filings and public trade sources, runs through a multi-layer quality process, and lands in a clean, consistent report you can rely on.
S FOR SUPPLIERS
Every competitor benchmark, market share figure, and buyer list in this report comes from verified commercial shipments — not surveys or estimates. Use them with confidence when planning your next pitch.
B FOR BUYERS
Every supplier profile, price benchmark, and trade route in this report reflects what that supplier actually ships — real volumes, real destinations, real prices. Use them to qualify and compare Indian lorazepam suppliers.
§2.1 Reporting parameters · the scope of this 2025-Q4 Lorazepam India trade report
Product scope
Lorazepam
All variants merged — branded and generic formulations of lorazepam
Time period
2025-Q4
October, November, December 2025 — a single-quarter snapshot
Data sources
Official & public trade records
Government customs filings, public trade databases and licensed commercial feeds
Geography
India origin → global
Indian sea and air ports shipping to destination markets worldwide
Currency
USD (FOB)
Declared Free-on-Board value at the Indian port of loading
Shipments analysed
24
Every commercial lorazepam trade record in the period, aggregated and deduplicated
§2.2 Our quality process · Figure 2.1
Figure 2.1 From raw trade records to a clean report — the four quality pillars.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Raw trade data (left) flows through four quality checks — source verification, format standardisation, entity matching, and deduplication — to produce the clean, reliable data (right) behind every chart and table in this report.
§2.3 Trust signals · what you can rely on in the numbers you read
DATA COVERAGE
10M+
Pharmaceutical trade records across the full TransData Nexus platform.
COUNTRIES
150+
Origin and destination countries covered in the global pharma trade database.
DATA ACCURACY
99.9%
Validation rate on core fields — supplier, buyer, product, quantity, value.
UPDATE FREQUENCY
Daily
Platform refresh cadence. This report is a snapshot from the same live data.
§2.4 Limitations · what the data does and does not tell you
WHAT THIS DATA DOES AND DOES NOT SAY
- Prices are at the Indian port of loading (FOB), not the final delivered cost in the destination country. Freight, insurance, import duty and local margin are not included.
- This is a single-quarter snapshot. Multi-quarter trends, year-over-year growth and historical comparisons are available on the full platform.
- A small number of records have incomplete transport mode or destination port fields; these appear blank in the shipment register but are still counted in totals.
- This report is a commercial intelligence tool, not a legal audit. For high-stakes decisions, cross-reference with the underlying trade records via the full platform.
03
PART II — MARKET STRUCTURE
Quarterly Trade Overview
Monthly trends, regional performance, and ranking shifts — 2025-Q4
KEY TAKEAWAY
2025-Q4 followed a v-curve: Oct $109.2K, Nov $73.8K, Dec $180.2K. Shipment counts were mixed across the quarter.
S FOR SUPPLIERS
Track which months your competitors were most active, which destinations rose or fell, and whether the Nov dip hit your segment. The bump charts show rank movement — watch for rivals climbing past you.
B FOR BUYERS
Identify whether your current Indian supplier maintained steady shipments through the quarter, or whether they pulled back. Steady suppliers during dips signal reliable partnerships.
1
$109.2K
Oct USD
8 shipments
2
$73.8K
Nov USD
-32.4% MoM
3
$180.2K
Dec USD
+144.2% MoM
4
V-curve
Q4 growth shape
Oct → Nov → Dec
Fig 3.1 Nov dipped 32.4% in USD but shipment count kept climbing.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = monthly USD. Orange line = shipment count. When bars drop but line rises, average shipment value fell. Insight: Oct opened at $109K, making it the middle month by value.
Fig 3.2 Q4 cumulative USD reached $363K.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The curve shows the running total across the quarter. A steeper slope means that month contributed more revenue. Insight: The curve’s steepest section reveals which month drove the most trade value.
Fig 3.3 $35K dip in Nov, $106K recovery in Dec.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Blue bars = absolute monthly value. Red = month-over-month loss; green = gain. Insight: Nov’s dip was fully recovered by Dec.
Fig 3.4 Regional breakdown by month — which corridors swung most?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each coloured layer is one destination region. Layer height = USD in that month. Insight: The top region contributed the most, while the smallest region had the least volume.
§3.1 Monthly summary
| Oct | $109K | 8 shipments |
| Nov | $74K | 9 shipments |
| Dec | $180K | 7 shipments |
| Q4 Total | $363K | 24 shipments |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 3.5 Top 10 destination countries by monthly USD rank — who’s rising?
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a country’s monthly rank. Lines crossing = rank swaps. Insight: United States held #1 throughout the quarter.
Fig 3.6 Top 10 Indian exporters by monthly USD rank.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each line traces a supplier’s monthly rank. Flat = stable position; crossing = rank change. Insight: ESJAY PHARMA PVT LTD maintained its leading position.
04
PART II — MARKET STRUCTURE
Global Destination Map
Which countries import lorazepam from India, how much they buy, and who supplies each market
KEY TAKEAWAY
United States absorbs 55.7% of India’s 2025-Q4 lorazepam trade ($202.3K). Beyond the top 10 destinations, 10 countries have fewer than 5 Indian suppliers each — white-space markets where new entrants face minimal competition. Asia has 4 destination countries, the widest regional diversity.
S FOR SUPPLIERS
Use the flow map and lanes table to see which destinations your competitors dominate. For small and mid-size suppliers: look beyond the leading markets — the 10 countries in the long tail have fewer than 5 Indian suppliers each and low competitive barriers.
B FOR BUYERS
Find your country on the map to see how much lorazepam India ships to your market, who the top suppliers are, and whether you’re in a concentrated or competitive corridor.
Asia
$66K
18.1% of trade
4 countries · 7 shipments
Europe
$54K
14.9% of trade
2 countries · 8 shipments
Americas
$202K
55.7% of trade
1 countries · 6 shipments
Africa
$41K
11.4% of trade
3 countries · 3 shipments
Fig 4.1 United States is the #1 corridor ($202K) — 10 flow arcs from India radiate across 4 continents.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: The world map shows every country colored by how much Indian lorazepam it receives (light = low, dark = high). Orange arcs radiate from India to the top 10 destinations; arc thickness = USD value. All destinations are labeled with country name + USD.
§4.1 Top 10 bilateral trade lanes (India → destination) with top Indian suppliers
| # | Destination | Total USD | Ships | #1 Indian supplier | USD | #2 Indian supplier | USD | #3 Indian supplier | USD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | United States | $202K | 6 | ESJAY PHARMA PVT LTD | $202K | — | — | — | — |
| 2 | South Africa | $35K | 1 | ALPHAMED FORMULATIONS PVT LTD | $35K | — | — | — | — |
| 3 | Myanmar | $34K | 3 | SURAKSHA PHARMA PVT LTD | $34K | — | — | — | — |
| 4 | United Kingdom | $30K | 3 | J B CHEMICALS AND PHARMACEUTICALS LTD | $30K | — | — | — | — |
| 5 | Malta | $24K | 5 | AUROBINDO PHARMA LTD | $24K | — | — | — | — |
| 6 | Afghanistan | $20K | 1 | LARK LABORATORIES (INDIA) LTD | $20K | — | — | — | — |
| 7 | Qatar | $8K | 1 | CADILA PHARMACEUTICALS LTD | $8K | — | — | — | — |
| 8 | Kenya | $6K | 1 | VENOR PHARMA LTD | $6K | — | — | — | — |
| 9 | Singapore | $3K | 2 | AALTOP HEALTHCARE PVT LTD | $3K | — | — | — | — |
| 10 | Ethiopia | $50 | 1 | SCOTT EDIL PHARMACIA LTD | $50 | — | — | — | — |
Table 4.1 — Top 10 destination countries ranked by trade value, with the largest Indian suppliers for each market.
Fig 4.2 Asia leads at 18.1% of USD — but United States is the single largest market.
Region → country treemap
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Column width = region USD share. Within each column, cells are stacked by country, height = share within region.
§4.2 Destination concentration
55.7%
#1 country share
United States alone
89.4%
Top 5 share
5 of 10 countries
100.0%
Top 15 share
Long tail of -5 countries = 0.0%
HHI 3432
Destination HHI
Highly concentrated
10
Countries served
Global pharma reach from India
4
Asia countries
Widest regional diversity
Source: TransData Nexus trade data platform
05
PART III — WHO’S IN THIS MARKET
Indian Supplier Rankings & Profiles
10 Indian exporters ranked by value — profiles, portfolios, and competitive intelligence
KEY TAKEAWAY
ESJAY PHARMA PVT LTD ($202.3K, 55.7% share) and ALPHAMED FORMULATIONS PVT LTD ($34.9K) together control 65.3% of India’s 2025-Q4 lorazepam trade. The top 5 suppliers hold 89.4%. 10 companies shipped at least once.
S FOR SUPPLIERS
Find your rank, your competitors’ ranks, and the gap in USD/share between you. The profile pages show each top supplier’s buyer portfolio, dosage mix and route map — your competitive-intelligence toolkit.
B FOR BUYERS
Find potential Indian lorazepam suppliers ranked by size, catalog breadth and destination reach. The profile pages reveal which suppliers have proven trade lanes to your region.
Fig 5.1 ESJAY PHARMA PVT LTD leads by $167K over ALPHAMED FORMULATIONS PVT LTD — top 10 Indian exporters ranked by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian supplier ranked by USD. The (#N) shows their rank by shipment count — mismatches reveal pricing strategy. Insight: ALPHAMED FORMULATIONS PVT is #2 by value but #6 by volume.
Fig 5.2 ESJAY PHARMA PVT LTD also leads by shipment count (6) but ranking shifts for volume-heavy players
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same suppliers re-ranked by shipment count. The (#N) shows their rank by USD value. Insight: ALPHAMED FORMULATIONS PVT moves from #6 by volume to #2 by value — fewer but higher-value shipments.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — Archetypes & Concentration
How India’s 10 lorazepam suppliers split into strategic segments
KEY TAKEAWAY
3 suppliers (25%) generate 74.6% of total trade value. The market splits into four archetypes: Market Leaders, High-Value specialists, Volume players, and a long tail.
Fig 5.3 ESJAY PHARMA PVT LTD and ALPHAMED FORMULATIONS PVT LTD sit in the leaders zone — high volume AND high value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble is one Indian supplier. X-axis = shipment count (log scale); Y-axis = total USD value (log scale); bubble size = revenue. Blue dashed lines split at the median. Market Leaders (top-right) combine high volume with high value. Premium Niche (top-left) ship fewer but higher-value consignments. Volume Players (bottom-right) compete on quantity. Long-Tail (bottom-left) are small or occasional exporters. Conclusion: the log scale reveals clear strategic clusters — use this map to identify where your company sits relative to competitors.
Fig 5.4 25% of suppliers = 74.6% of USD — classic concentration.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Top bar = supplier %, bottom bar = USD %. The gap = market concentration.
Product variety — how many formulations each supplier ships
| # | Supplier | Dosage forms | Countries | USD |
|---|---|---|---|---|
| 1 | ESJAY PHARMA PVT LTD | 1 | 1 | $202K |
| 2 | ALPHAMED FORMULATIONS PVT LTD | 1 | 1 | $35K |
| 3 | SURAKSHA PHARMA PVT LTD | 1 | 1 | $34K |
| 4 | J B CHEMICALS AND PHARMACEUTICALS LTD | 1 | 1 | $30K |
| 5 | AUROBINDO PHARMA LTD | 1 | 1 | $24K |
| 6 | LARK LABORATORIES (INDIA) LTD | 1 | 1 | $20K |
| 7 | VENOR PHARMA LTD | 1 | 1 | $6K |
| 8 | AALTOP HEALTHCARE PVT LTD | 1 | 1 | $3K |
| 9 | SCOTT EDIL PHARMACIA LTD | 1 | 1 | $50 |
| 10 | CADILA PHARMACEUTICALS LTD | 0 | 1 | $8K |
Table 5.1 — The more dosage forms a supplier ships, the more versatile their manufacturing capability.
05
PART III — WHO’S IN THIS MARKET
Supply Landscape — India Origin Geography & Concentration
Which Indian cities and states are the lorazepam manufacturing hubs
KEY TAKEAWAY
Kancheepuram and Medchal-Malkakgiri District together account for $237K of India’s 2025-Q4 lorazepam trade.
Fig 5.5 Kancheepuram (1 exporters, $202K) and Medchal-Malkakgiri District (1 exporters, $35K) are India’s lorazepam capitals.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Orange bubbles mark major pharma hub cities; bubble size = USD value. Every hub labeled.
§5.1 Supplier concentration metrics
89.4%
Top 5 share
5 of 10 suppliers
100.0%
Top 10 share
10 of 10 suppliers
74.6%
Top 25% share
3 suppliers = 75% USD
HHI 3432
Supplier HHI
Concentrated
10
Total suppliers
shipped Lorazepam in 2025-Q4
9+ cities
Indian hubs
Kancheepuram and Medchal-Malkakgiri District lead
§5.2 Coming next: 0 exporter deep-dive profiles
Each of the top 0 suppliers gets a dedicated 2-page profile with:
- 6 KPI cards — trade value, shipments, countries, buyers, avg ship value, branded share
- Dosage form breakdown — what formulations they ship
- Monthly trend — Oct / Nov / Dec trajectory
- Trade flow map — supplier → country → importer connections
- Buyer portfolio with lock-in analysis
SUPPLIER PROFILES IN THIS REPORT
06
PART III — WHO’S IN THIS MARKET
Global Buyer Rankings & Intelligence
10 importers across 10 countries — who is buying Indian lorazepam and how much
KEY TAKEAWAY
The demand side is dramatically more fragmented than supply: the top 9 importers together hold only 100.0% of total USD. 100% of buyers source from a single Indian supplier — a vast pool of lock-in candidates.
S FOR SUPPLIERS
Find the importers buying from your competitors. The rankings reveal who has volume, who pays well, and who sources from multiple Indian suppliers (potential pitch targets).
B FOR BUYERS
See where you rank among global importers of Indian lorazepam. Compare your USD and shipment count against peers in your country and dosage segment.
Fig 6.1 THE PURCHASE MANAGER is the #1 importer at $202K (55.7%) — top 9 by trade value
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one global importer ranked by USD.
Fig 6.2 Re-ranked by shipment count — compare with Fig 6.1 for divergences
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Same 9 importers re-ranked by shipment count.
§6.1 Sourcing diversity — how many Indian suppliers does each buyer use?
100%
Single-source
10 buyers rely on exactly 1 Indian supplier
0%
Dual-source
0 buyers use 2 Indian suppliers
0%
Multi-source (3–4)
0 buyers diversified across 3–4
0%
Broad-source (5+)
0 buyers with 5+ Indian suppliers
06
PART III — WHO’S IN THIS MARKET
Single-Source Buyers & Price Benchmark
Lock-in opportunities grouped by country + where each buyer sits on the price spectrum
KEY TAKEAWAY
These importers source lorazepam from exactly one Indian supplier. For each one, the table shows the incumbent, price, and dosage.
S FOR SUPPLIERS
This is your target list. Each row is a buyer locked into one competitor. Offer 5–10% better pricing to win the second-source slot.
B FOR BUYERS
If you see your company here, you are fully dependent on one Indian supplier. Consider qualifying a second source.
§6.2 Single-source lock-in by country
United States 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| THE PURCHASE MANAGER | ESJAY PHARMA PVT LTD | $202K | $2.876 | Tablet |
South Africa 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| ASPEN CENTRALISED WARE… | ALPHAMED FORMULATION… | $35K | $0.672 | Capsule |
Myanmar 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| THU KHA EAI TRADING CO… | SURAKSHA PHARMA PVT … | $34K | $1.378 | Tablet |
United Kingdom 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| GENESIS PHARMACEUTICAL… | J B CHEMICALS AND PH… | $30K | $0.695 | Tablet |
Malta 1 single-source buyers
| Importer | Current supplier | USD | Unit $ | Dosage |
|---|---|---|---|---|
| APL SWIFT SERVICES (MA… | AUROBINDO PHARMA LTD | $24K | $0.010 | Tablet |
§6.3 Price positioning — top 9 importers
| # | Importer | Country | USD | $/ship | Tier |
|---|---|---|---|---|---|
| 1 | THE PURCHASE MANAGER | United States | $202K | $34K | Mid |
| 2 | ASPEN CENTRALISED WA… | South Africa | $35K | $35K | Mid |
| 3 | THU KHA EAI TRADING … | Myanmar | $34K | $11K | Budget |
| 4 | GENESIS PHARMACEUTIC… | United Kingdom | $30K | $10K | Budget |
| 5 | APL SWIFT SERVICES (… | Malta | $24K | $5K | Budget |
| 6 | MASEEH AMIRZAI LTD | Afghanistan | $20K | $20K | Mid |
| 7 | QATAR LIFE FACTORY | Qatar | $8K | $8K | Budget |
| 8 | M/S.GENERICS AFRICA … | Kenya | $6K | $6K | Budget |
| 9 | ALSTERN MARINE & OFF… | Singapore | $3K | $2K | Budget |
06
PART III — WHO’S IN THIS MARKET
Market Relationship Map
The top 10 × 9 supplier ↔ buyer network as a circular flow diagram
Fig 6.3 ESJAY PHARMA PVT LTD → THE PURCHASE MANAGER is the strongest relationship.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left semicircle = top 10 Indian suppliers; right = top 9 global buyers. Arc length = total USD; colored ribbons = individual relationships, thickness = USD value. Insight: follow the thickest ribbons to identify the dominant trading pairs.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
How Indian lorazepam prices vary by supplier, country and dosage form
KEY TAKEAWAY
Lorazepam prices span 856× ($0.0080 → $6.82). The coefficient of variation is 1.20. Dosage form, not destination, is the primary price driver.
S FOR SUPPLIERS
Use the box plot to see where your product sits on the price spectrum. The tornado chart shows exactly where you sit relative to the market median.
B FOR BUYERS
Use this section to benchmark the price you pay against the market. The percentile strip tells you if your current supplier is charging you premium, mid-market or budget rates.
§7.1 Price distribution · Table 7.1
| Statistic | Value | Interpretation |
|---|---|---|
| Min | $0.0080 | Lowest observed unit price |
| P5 | $0.0084 | 5th percentile |
| P25 | $0.025 | 25th percentile (Q1) |
| Median | $0.700 | 50th percentile (Q2) |
| P75 | $2.99 | 75th percentile (Q3) |
| P95 | $6.12 | 95th percentile |
| Max | $6.82 | Highest observed unit price |
| Mean | $1.93 | Arithmetic average |
| CV | 120% | Coefficient of variation (std/mean) |
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
Fig 7.1 LARK LABORATORIES (INDIA) LTD prices at $6.82/unit vs market median $0.700.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar shows one supplier’s average unit price relative to the market median (dashed line). Red = above median (premium), green = below (budget).
COMMODITY KINGS
high volume · low unit price
Bulk API/tablet. Largest absolute USD despite lowest per-unit prices. e.g. AUROBINDO PHARMA LTD Sourcing: best for cost-driven procurement.
BULK LEADERS
high volume · premium price
Branded-generic leaders, above-median pricing. e.g. ESJAY PHARMA PVT Sourcing: hardest to displace; compete on relationship.
LONG-TAIL
low volume · low unit price
Spot/opportunistic players. e.g. ALPHAMED FORMULATIONS PVT Sourcing: first to approach for new tenders.
PREMIUM NICHE
low volume · premium price
Sterile injectables and infusions. Hospital-grade. e.g. LARK LABORATORIES (INDIA) Sourcing: expect 10× price vs tablet.
07
PART IV — MARKET BEHAVIOR
Price Benchmarks & Analysis
Outlier forensics and the procurement cheat sheet — what to expect to pay by country × dosage
KEY TAKEAWAY
Extreme prices are real: the highest are specialty/sterile formulations; the lowest are bulk API. The cheat sheet matrix is the take-home reference for procurement teams.
§7.2 Outlier forensics — top 10 highest and 10 lowest unit prices
↑ TOP 10 HIGHEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Oct 2025 | LARK LABORATORIE… | Afghanistan | Tablet | 3K | $20K | $6.82 | Specialty / small-batch |
| Dec 2025 | ESJAY PHARMA PVT… | United States | Tablet | 10K | $58K | $6.12 | Specialty / small-batch |
| Dec 2025 | ESJAY PHARMA PVT… | United States | Tablet | 10K | $58K | $6.12 | Specialty / small-batch |
| Nov 2025 | AALTOP HEALTHCAR… | Singapore | Tablet | 300 | $2K | $5.59 | Specialty / small-batch |
| Nov 2025 | AALTOP HEALTHCAR… | Singapore | Tablet | 300 | $2K | $5.59 | Specialty / small-batch |
| Dec 2025 | ESJAY PHARMA PVT… | United States | Tablet | 9K | $28K | $2.99 | Specialty / small-batch |
| Dec 2025 | ESJAY PHARMA PVT… | United States | Tablet | 9K | $28K | $2.99 | Specialty / small-batch |
| Nov 2025 | ESJAY PHARMA PVT… | United States | Tablet | 10K | $28K | $2.98 | Specialty / small-batch |
| Oct 2025 | SURAKSHA PHARMA … | Myanmar | Tablet | 10K | $13K | $1.38 | Specialty / small-batch |
| Oct 2025 | SURAKSHA PHARMA … | Myanmar | Tablet | 10K | $14K | $1.38 | Specialty / small-batch |
↓ TOP 10 LOWEST USD/UNIT
| Date | Exporter | Country | Dosage | Qty | USD | $/unit | Why |
|---|---|---|---|---|---|---|---|
| Nov 2025 | AUROBINDO PHARMA… | Malta | Tablet | 380K | $3K | $0.0080 | Bulk generic tablet |
| Oct 2025 | AUROBINDO PHARMA… | Malta | Tablet | 900K | $8K | $0.0084 | Bulk generic tablet |
| Nov 2025 | AUROBINDO PHARMA… | Malta | Tablet | 100K | $843.87 | $0.0084 | Bulk generic tablet |
| Oct 2025 | AUROBINDO PHARMA… | Malta | Tablet | 518K | $6K | $0.012 | |
| Oct 2025 | AUROBINDO PHARMA… | Malta | Tablet | 421K | $6K | $0.015 | |
| Nov 2025 | CADILA PHARMACEU… | Qatar | — | 384K | $8K | $0.022 | |
| Dec 2025 | SCOTT EDIL PHARM… | Ethiopia | Injection | 2K | $50.10 | $0.026 | Sterile formulation premium |
| Dec 2025 | ESJAY PHARMA PVT… | United States | Tablet | 23K | $854.00 | $0.037 | |
| Dec 2025 | VENOR PHARMA LTD | Kenya | Tablet | 140K | $6K | $0.045 | |
| Nov 2025 | J B CHEMICALS AN… | United Kingdom | Tablet | 6K | $4K | $0.665 |
§7.3 Procurement cheat sheet — median USD/unit by country × dosage
Fig 7.2 Median unit price by country × dosage form — darker cells = higher prices.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each cell shows the median price per unit for that country-dosage combination. Dark blue = expensive, light = cheap. Blank cells = no shipments in that combination.
NEGOTIATION RANGE
Use each cell value as the anchor price. Typical dynamics:
- Budget buyer: anchor − 10–15% (floor = cost + freight)
- Mid-market: anchor ± 5–10%
- Premium/tender: anchor + 10–25% (regulated, quality premium)
- Injection/infusion: always 4–10× the tablet price
KEY TAKEAWAYS
- Dosage form is the #1 price driver, not destination
- Light cells = easy-entry markets for small suppliers
- Dark cells = premium markets requiring regulatory investment
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Which Indian ports ship lorazepam, which global ports receive it, and which corridors are high-value vs bulk
KEY TAKEAWAY
Lorazepam leaves India through 9+ ports. The top 5 (CHENNAI AIR, HYDERABAD ICD, HYDERABAD AIR) handle 83.7% of total USD. AIR moves 42% of shipments.
S FOR SUPPLIERS
Use the dumbbell to classify your port as high-value hub or bulk workhorse. Note the short-sea routes — Bangladesh, Sri Lanka, Myanmar and East Africa are the easiest logistics corridors for first-time exporters.
B FOR BUYERS
Use the destination port ranking to find which Indian ports serve your market. The lead-time estimates tell you what transit time to expect.
Fig 8.1 CHENNAI AIR handles $173K — top 9 Indian origin ports by trade value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one Indian port. Bar length = USD value. The largest ports handle the majority of trade.
Fig 8.2 CHICAGO O'HARE INT'L is the #1 global destination port — top 12 by USD value.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bar = one destination port worldwide. Bar length = USD value received from India.
§8.1 Reference transit times for key India → global corridors
| Route | Mode | Transit time | Notes |
|---|---|---|---|
| NHAVA SHEVA SEA (JNPT) → US East Coast | Sea | 22–28 days | Via Suez; 2–3 transshipments typical |
| NHAVA SHEVA SEA (JNPT) → Lagos (Nigeria) | Sea | 18–24 days | Direct liner service available |
| MUMBAI AIR (SAHAR) → New York JFK | Air | 3–5 days | Direct cargo; cold-chain available |
| MUNDRA SEA → Rotterdam | Sea | 20–26 days | Via Suez; Hamburg also served |
| HYDERABAD AIR → London Heathrow | Air | 2–4 days | Pharma-grade cargo corridor |
| CHENNAI SEA → Chittagong (Bangladesh) | Sea | 7–12 days | Short-sea route; high frequency |
| RAXAUL → Birgunj (Nepal) | Road | 1–2 days | Land border crossing |
| NHAVA SHEVA SEA (JNPT) → Mombasa (Kenya) | Sea | 14–20 days | Direct or via Colombo hub |
Table 8.1 — Reference times based on standard shipping corridors. Air = 2–5 days; sea = 7–28 days; road = 1–2 days. Add 3–7 days for customs clearance at destination.
08
PART IV — MARKET BEHAVIOR
Shipping Ports & Trade Routes
Trade corridors — origin port to mode of transport to destination region
KEY TAKEAWAY
AIR dominates at 42% of shipments. The alluvial traces every dollar from Indian origin port through transport mode to destination region.
AIR
$221K
61.0% of USD · 41.7% of ships
SEA
$87K
23.8% of USD · 50.0% of ships
ICD
$55K
15.2% of USD · 8.3% of ships
Fig 8.3 The dominant corridor is CHENNAI AIR → Air → N. America ($173K).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Left = Indian origin ports. Middle = transport mode. Right = destination region. Ribbon thickness = USD value; color = mode. Follow the thickest ribbons to find the highest-value corridors.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market concentration, supply-chain risk, and the dependency patterns that signal where to act
KEY TAKEAWAY
United States is the most concentrated destination (HHI 10000, 1 suppliers). Ethiopia is the most competitive (HHI 10000).
S FOR SUPPLIERS
The HHI barbell shows where competitors have locked up a market (concentrated = poaching opportunity) vs where you must compete on quality (fragmented). The slope chart reveals who is gaining ground.
B FOR BUYERS
The HHI barbell tells you whether your country has enough supplier options. If concentrated (red zone), you have fewer alternatives.
Fig 9.1 United States (HHI 10,000) is the most concentrated — United States (HHI 10,000) is the most competitive.
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
What is HHI? The Herfindahl-Hirschman Index measures how concentrated a market is among its suppliers. It ranges from 0 to 10,000. Below 1,500 (green zone) = many suppliers compete openly — healthy, competitive market with low risk. 1,500–2,500 (yellow zone) = a few suppliers hold significant share — moderate concentration. Above 2,500 (red zone) = one or two suppliers dominate the market — high risk for buyers who may lose supply, and hard to break into for new suppliers. Conclusion: 10 of 10 destination markets are concentrated (red zone). 0 are competitive (green zone). Buyers in red-zone markets should urgently qualify a second Indian supplier to reduce dependency risk.
§9.1 Single-source dependencies
| Buyer | Country | Sole supplier | USD | Ships | Risk |
|---|---|---|---|---|---|
| THE PURCHASE MANAGER | United States | ESJAY PHARMA PVT… | $202K | 6 | HIGH |
| ASPEN CENTRALISED WA… | South Africa | ALPHAMED FORMULA… | $35K | 1 | MEDIUM |
| THU KHA EAI TRADING … | Myanmar | SURAKSHA PHARMA … | $34K | 3 | MEDIUM |
| GENESIS PHARMACEUTIC… | United Kingdom | J B CHEMICALS AN… | $30K | 3 | MEDIUM |
| APL SWIFT SERVICES (… | Malta | AUROBINDO PHARMA… | $24K | 5 | MEDIUM |
| MASEEH AMIRZAI LTD | Afghanistan | LARK LABORATORIE… | $20K | 1 | MEDIUM |
| QATAR LIFE FACTORY | Qatar | CADILA PHARMACEU… | $8K | 1 | MEDIUM |
| M/S.GENERICS AFRICA … | Kenya | VENOR PHARMA LTD | $6K | 1 | MEDIUM |
Conclusion: 9 buyers depend on exactly one Indian supplier, representing $363K in trade. For suppliers: each row is a competitor’s locked-in customer you can target.
§9.2 Multi-source resilience
| Buyer | Country | Suppliers | USD | Dominant | Resilience |
|---|
Conclusion: 0 of these buyers have HIGH resilience (3+ active suppliers). These are the hardest accounts to win but safest partners for long-term contracts.
09
PART V — ACTION
Strategic Opportunities & Action Plan
Market entry playbook and risk landscape by destination country
KEY TAKEAWAY
15 target markets with specific entry approaches. Large suppliers: focus on regulated Tier 1 markets. Small/mid-size: start with Tier 2–3 (low barrier, growing demand).
§9.3 Sourcing recommendations · Table 9.1
| Country | Tier | Lead | Price | Risk | Entry approach |
|---|---|---|---|---|---|
| United States | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| South Africa | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Myanmar | Tier 3 (emerging) | 3–5 days (air) | $1–$10/unit | LOW | First-mover advantage |
| United Kingdom | Tier 3 (emerging) | 14–28 days (sea) | $0.10–$1/unit | LOW | First-mover advantage |
| Malta | Tier 3 (emerging) | 14–28 days (sea) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Afghanistan | Tier 3 (emerging) | 14–28 days (sea) | $1–$10/unit | LOW | First-mover advantage |
| Qatar | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Kenya | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
| Singapore | Tier 3 (emerging) | 14–28 days (sea) | $1–$10/unit | LOW | First-mover advantage |
| Ethiopia | Tier 3 (emerging) | 3–5 days (air) | $0.01–$0.10/unit | LOW | First-mover advantage |
For suppliers: Tier 1 markets (US, UK, France) require regulatory investment but offer premium pricing. Tier 3 markets (emerging) have low barriers — ideal for first-time exporters. For buyers: Use the price band and lead time to benchmark your current supplier’s terms.
Fig 9.2 0 markets in the Growth Opportunity zone (competitive + growing). 10 in Fragile Dependency (concentrated + shrinking).
Source: TransData Nexus Pharma Trade Intelligence · Licensed database & govt sources
How to read: Each bubble = one destination. X-axis = HHI (concentration). Y-axis = growth %. Bubble size = USD. Green zone (top-left) = Growth Opportunity — competitive markets that are growing, best for new entrants. Red zone (bottom-right) = Fragile Dependency — concentrated + shrinking, high supply-chain risk. Conclusion: Key markets are the top growth opportunities.
09
PART V — ACTION
Action Plan & Easy-Entry Markets
12 prioritised actions + 10 low-competition destination countries for small & mid-size suppliers
KEY TAKEAWAY
Quick Wins: execute this quarter. Big Bets: plan for next 6–12 months. Plus 10 countries with ≤5 Indian suppliers — the best entry points for SMEs.
S
FOR SUPPLIERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A1 | Pitch top single-source buyer in United States | This Q | HIGH |
| A2 | Offer alternative to top multi-source buyer | This Q | HIGH |
| A3 | Audit United States lock-ins (HHI 10000) | This Q | MED |
| A5 | Enter United States (1 suppliers) | This Q | HIGH |
| A6 | Enter South Africa (1 suppliers) | This Q | MED |
| A8 | Build South Africa distribution | 6–12m | HIGH |
| A9 | Bundle injection/infusion catalog for premium markets | 6–12m | MED |
B
FOR BUYERS
| ID | Action | Timing | Impact |
|---|---|---|---|
| A4 | Monitor rising exporters (climbers) | This Q | MED |
| A7 | Register for United States tenders | 6–12m | HIGH |
| A10 | Track quarterly HHI shifts across key destinations | This Q | LOW |
| A11 | Map competitor buyer portfolios quarterly | This Q | MED |
| A12 | Qualify second source for single-source buyers | This Q | MED |
§9.4 Easy-entry markets — 10 countries with ≤5 Indian suppliers
| # | Country | Region | Suppliers | Q4 USD | Growth | Barrier | Why this is easy |
|---|---|---|---|---|---|---|---|
| 1 | United States | Other | 1 | $202K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 2 | South Africa | Africa | 1 | $35K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 3 | Myanmar | Asia | 1 | $34K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 4 | United Kingdom | Other | 1 | $30K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 5 | Malta | Other | 1 | $24K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 6 | Afghanistan | Asia | 1 | $20K | -100% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 7 | Qatar | Other | 1 | $8K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 8 | Kenya | Africa | 1 | $6K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 9 | Singapore | Asia | 1 | $3K | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
| 10 | Ethiopia | Africa | 1 | $50 | 0% | LOW | Only 1 Indian suppliers — near-monopoly, easy second-source entry |
This report covers 24 2025-Q4 Lorazepam shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/lorazepam
10
PART VI — EVIDENCE REGISTER
Comprehensive Shipment Records by Region
Authoritative source behind all analytics in this report — every shipment appears exactly once
KEY TAKEAWAY
This section contains every one of the 24 2025-Q4 lorazepam shipments, organised by Region → Exporter → Shipment rows. No row is duplicated.
S FOR SUPPLIERS
Jump to any destination country to see exactly who your competitors ship to, what they charge, through which port, and how often.
B FOR BUYERS
Jump to your country to see every Indian lorazepam shipment that arrived in 2025-Q4: supplier, price, dosage, port.
§10.1 Global totals
SHIPMENTS
24
across all regions
TOTAL USD
$363K
2025-Q4 FOB value
UNITS
3.0M
tablets, capsules, etc.
SUPPLIERS
10
Indian exporters
BUYERS
10
global importers
COUNTRIES
10
destinations
§10.2 Regional breakdown
§10.3 Key insights from the data
Africa is the largest region at $41K (11.4%), spanning 3 countries.
10 Indian suppliers shipped to 10 buyers across 10 countries — average shipment value $15K.
Top 0 markets: .
Every row below is real customs data — date, importer, dosage, brand, quantity, unit price, total USD, origin port, destination port, and transport mode.
§10.4 How to read a country page
1
6 KPI cards — shipments, USD, qty, exporters, importers, avg unit price.
2
4 mini-lists — top exporters, importers, dosages, monthly trend.
3
Shipment register — every row grouped by exporter. No row is duplicated or omitted.
10
PART VI — DRILL-DOWN · AFRICA
Region: Africa
3 countries · 3 shipments · $41K · 3 Indian suppliers · 3 buyers
SHIPMENTS
3
USD
$41K
COUNTRIES
3
SUPPLIERS
3
BUYERS
3
HHI
7,388
concentrated
Top 3 destination countries in Africa
1
South Africa (84.6%)
$35K
2
Kenya (15.3%)
$6K
3
Ethiopia (0.1%)
$50.10
Top 3 Indian suppliers into Africa
1
ALPHAMED FORMULATIONS PVT LTD
$35K
2
VENOR PHARMA LTD
$6K
3
SCOTT EDIL PHARMACIA LTD
$50.10
Top 2 Africa importers
1
ASPEN CENTRALISED WAREHOUSE · South Africa
$35K
2
M/S.GENERICS AFRICA LTD · Kenya
$6K
Top 3 dosage forms
1
Capsule
$35K
2
Tablet
$6K
3
Injection
$50.10
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 1 | $35K | $35K |
| Nov | 0 | $0.0000 | — |
| Dec | 2 | $6K | $3K |
Shipment register · 3 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — ALPHAMED FORMULATIONS PVT LTD · 1 shipments · $35K | |||||||||||
| 1 | Oct 2025 | ASPEN CENTRALISED WAREHOUSE | South Africa | Capsule | 52.0K | NOS | $0.672 | $35K | HYDERABAD ICD | PORT ELIZABETH | ICD |
| SUPPLIER #2 — VENOR PHARMA LTD · 1 shipments · $6K | |||||||||||
| 2 | Dec 2025 | M/S.GENERICS AFRICA LTD | Kenya | Tablet | 140.0K | NOS | $0.045 | $6K | DELHI AIR | NAIROBI | AIR |
| SUPPLIER #3 — SCOTT EDIL PHARMACIA LTD · 1 shipments · $50.10 | |||||||||||
| 3 | Dec 2025 | UNLISTED BUYER | Ethiopia | Injection | 2.0K | NOS | $0.026 | $50.10 | DELHI AIR | ADDIS ABABA | AIR |
10
PART VI — DRILL-DOWN · ASIA
Region: Asia
4 countries · 7 shipments · $66K · 4 Indian suppliers · 4 buyers
SHIPMENTS
7
USD
$66K
COUNTRIES
4
SUPPLIERS
4
BUYERS
4
HHI
3,775
concentrated
Top 4 destination countries in Asia
1
Myanmar (51.3%)
$34K
2
Afghanistan (30.9%)
$20K
3
Qatar (12.7%)
$8K
4
Singapore (5.1%)
$3K
Top 4 Indian suppliers into Asia
1
SURAKSHA PHARMA PVT LTD
$34K
2
LARK LABORATORIES (INDIA) LTD
$20K
3
CADILA PHARMACEUTICALS LTD
$8K
4
AALTOP HEALTHCARE PVT LTD
$3K
Top 4 Asia importers
1
THU KHA EAI TRADING CO LTD · Myanmar
$34K
2
MASEEH AMIRZAI LTD · Afghanistan
$20K
3
QATAR LIFE FACTORY · Qatar
$8K
4
ALSTERN MARINE & OFFSHORE PTE LTD · Singapore
$3K
Top 2 dosage forms
1
Tablet
$57K
2
Unknown
$8K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 4 | $54K | $14K |
| Nov | 3 | $12K | $4K |
| Dec | 0 | $0.0000 | — |
Shipment register · 7 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — SURAKSHA PHARMA PVT LTD · 3 shipments · $34K | |||||||||||
| 1 | Oct 2025 | THU KHA EAI TRADING CO LTD | Myanmar | Tablet | 9.8K | NOS | $1.38 | $13K | HYDERABAD AIR | YANGON | AIR |
| 2 | Oct 2025 | THU KHA EAI TRADING CO LTD | Myanmar | Tablet | 9.8K | NOS | $1.38 | $14K | HYDERABAD AIR | YANGON | AIR |
| 3 | Oct 2025 | THU KHA EAI TRADING CO LTD | Myanmar | Tablet | 4.9K | NOS | $1.38 | $7K | HYDERABAD AIR | YANGON | AIR |
| SUPPLIER #2 — LARK LABORATORIES (INDIA) LTD · 1 shipments · $20K | |||||||||||
| 4 | Oct 2025 | MASEEH AMIRZAI LTD | Afghanistan | Tablet | 3.0K | NOS | $6.82 | $20K | TUGHLAKABAD ICD | Kandahar | ICD |
| SUPPLIER #3 — CADILA PHARMACEUTICALS LTD · 1 shipments · $8K | |||||||||||
| 5 | Nov 2025 | QATAR LIFE FACTORY | Qatar | 384.0K | TBS | $0.022 | $8K | AHMEDABAD AIR | DOHA | AIR | |
| SUPPLIER #4 — AALTOP HEALTHCARE PVT LTD · 2 shipments · $3K | |||||||||||
| 6 | Nov 2025 | ALSTERN MARINE & OFFSHORE PTE LTD | Singapore | Tablet | 300 | NOS | $5.59 | $2K | NHAVA SHEVA SEA (JNPT) | Singapore | SEA |
| 7 | Nov 2025 | ALSTERN MARINE & OFFSHORE PTE LTD | Singapore | Tablet | 300 | NOS | $5.59 | $2K | NHAVA SHEVA SEA (JNPT) | Singapore | SEA |
10
PART VI — DRILL-DOWN · EUROPE
Region: Europe
2 countries · 8 shipments · $54K · 2 Indian suppliers · 2 buyers
SHIPMENTS
8
USD
$54K
COUNTRIES
2
SUPPLIERS
2
BUYERS
2
HHI
5,055
concentrated
Top 2 destination countries in Europe
1
United Kingdom (55.2%)
$30K
2
Malta (44.8%)
$24K
Top 2 Indian suppliers into Europe
1
J B CHEMICALS AND PHARMACEUTICALS LTD
$30K
2
AUROBINDO PHARMA LTD
$24K
Top 2 Europe importers
1
GENESIS PHARMACEUTICALS LTD · United Kingdom
$30K
2
APL SWIFT SERVICES (MALTA) LTD · Malta
$24K
Top 1 dosage forms
1
Tablet
$54K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 3 | $20K | $7K |
| Nov | 5 | $34K | $7K |
| Dec | 0 | $0.0000 | — |
Shipment register · 8 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — J B CHEMICALS AND PHARMACEUTICALS LTD · 3 shipments · $30K | |||||||||||
| 1 | Nov 2025 | GENESIS PHARMACEUTICALS LTD | United Kingdom | Tablet | 6.4K | NOS | $0.665 | $4K | NHAVA SHEVA SEA (JNPT) | Felixstowe | SEA |
| 2 | Nov 2025 | GENESIS PHARMACEUTICALS LTD | United Kingdom | Tablet | 9.9K | NOS | $0.700 | $7K | NHAVA SHEVA SEA (JNPT) | Felixstowe | SEA |
| 3 | Nov 2025 | GENESIS PHARMACEUTICALS LTD | United Kingdom | Tablet | 26.6K | NOS | $0.700 | $19K | NHAVA SHEVA SEA (JNPT) | Felixstowe | SEA |
| SUPPLIER #2 — AUROBINDO PHARMA LTD · 5 shipments · $24K | |||||||||||
| 4 | Oct 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 518.4K | NOS | $0.012 | $6K | VIZAG SEA | MALTA FREEPORT DISTR | SEA |
| 5 | Oct 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 900.0K | NOS | $0.0084 | $8K | VIZAG SEA | MALTA FREEPORT DISTR | SEA |
| 6 | Oct 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 421.2K | NOS | $0.015 | $6K | VIZAG SEA | MALTA FREEPORT DISTR | SEA |
| 7 | Nov 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 380.0K | NOS | $0.0080 | $3K | VIZAG SEA | MALTA (VALETTA) | SEA |
| 8 | Nov 2025 | APL SWIFT SERVICES (MALTA) LTD | Malta | Tablet | 100.0K | NOS | $0.0084 | $843.87 | VIZAG SEA | MALTA (VALETTA) | SEA |
10
PART VI — DRILL-DOWN · AMERICAS
Region: Americas
1 countries · 6 shipments · $202K · 1 Indian suppliers · 1 buyers
SHIPMENTS
6
USD
$202K
COUNTRIES
1
SUPPLIERS
1
BUYERS
1
HHI
10,000
concentrated
Top 1 destination countries in Americas
1
United States (100.0%)
$202K
Top 1 Indian suppliers into Americas
1
ESJAY PHARMA PVT LTD
$202K
Top 1 Americas importers
1
THE PURCHASE MANAGER · United States
$202K
Top 1 dosage forms
1
Tablet
$202K
Monthly trend
| Month | Ships | USD | Avg/ship |
|---|---|---|---|
| Oct | 0 | $0.0000 | — |
| Nov | 1 | $28K | $28K |
| Dec | 5 | $174K | $35K |
Shipment register · 6 rows · grouped by exporter
| # | Date | Importer | Country | Dosage | Qty | Unit | Unit $ | Total $ | Origin | Dest | Mode |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPPLIER #1 — ESJAY PHARMA PVT LTD · 6 shipments · $202K | |||||||||||
| 1 | Nov 2025 | THE PURCHASE MANAGER | United States | Tablet | 9.5K | NOS | $2.98 | $28K | CHENNAI SEA | New York | SEA |
| 2 | Dec 2025 | THE PURCHASE MANAGER | United States | Tablet | 9.5K | NOS | $2.99 | $28K | CHENNAI AIR | CHICAGO O'HARE INT'L | AIR |
| 3 | Dec 2025 | THE PURCHASE MANAGER | United States | Tablet | 9.5K | NOS | $6.12 | $58K | CHENNAI AIR | CHICAGO O'HARE INT'L | AIR |
| 4 | Dec 2025 | THE PURCHASE MANAGER | United States | Tablet | 9.5K | NOS | $2.99 | $28K | CHENNAI AIR | CHICAGO O'HARE INT'L | AIR |
| 5 | Dec 2025 | THE PURCHASE MANAGER | United States | Tablet | 9.5K | NOS | $6.12 | $58K | CHENNAI AIR | CHICAGO O'HARE INT'L | AIR |
| 6 | Dec 2025 | THE PURCHASE MANAGER | United States | Tablet | 22.9K | NOS | $0.037 | $854.00 | CHENNAI SEA | New York | SEA |
10
PART VI — EVIDENCE REGISTER
Indian Supplier Directory
All 10 Indian lorazepam exporters — complete list ranked by USD
KEY TAKEAWAY
This directory lists every Indian company that shipped lorazepam in 2025-Q4.
S FOR SUPPLIERS
Find yourself and your competitors. Compare shipment count, USD, and destination regions.
B FOR BUYERS
Search for potential Indian suppliers. Filter by dosage form and destination region.
| # | Supplier | City | Ships | USD | Dosage forms | Primary regions |
|---|---|---|---|---|---|---|
| 1 | ESJAY PHARMA PVT LTD | Kancheepuram | 6 | $202K | Tablet | Americas |
| 2 | ALPHAMED FORMULATIONS PVT LTD | MEDCHAL-MALKAKGIRI DISTRICT | 1 | $35K | Capsule | Africa |
| 3 | SURAKSHA PHARMA PVT LTD | HYDERABAD | 3 | $34K | Tablet | Asia |
| 4 | J B CHEMICALS AND PHARMACEUTICALS LTD | WORLI MUMBAI | 3 | $30K | Tablet | Europe |
| 5 | AUROBINDO PHARMA LTD | PARAWADA | 5 | $24K | Tablet | Europe |
| 6 | LARK LABORATORIES (INDIA) LTD | NEW DELHI | 1 | $20K | Tablet | Asia |
| 7 | CADILA PHARMACEUTICALS LTD | AHMEDABAD | 1 | $8K | Asia | |
| 8 | VENOR PHARMA LTD | NEW DELHI | 1 | $6K | Tablet | Africa |
| 9 | AALTOP HEALTHCARE PVT LTD | MUMBAI | 2 | $3K | Tablet | Asia |
| 10 | SCOTT EDIL PHARMACIA LTD | BADDI | 1 | $50.10 | Injection | Africa |
10
PART VI — EVIDENCE REGISTER
Global Buyer Directory
All 9 global lorazepam importers — complete list ranked by USD
KEY TAKEAWAY
This directory lists every company that imported Indian lorazepam in 2025-Q4.
S FOR SUPPLIERS
Search for potential customers by country and dosage form.
B FOR BUYERS
Find your company and see which Indian supplier serves you.
| # | Buyer | Country | Ships | USD | Primary supplier | Dosage forms |
|---|---|---|---|---|---|---|
| 1 | THE PURCHASE MANAGER | United States | 6 | $202K | ESJAY PHARMA PVT LTD | Tablet |
| 2 | ASPEN CENTRALISED WAREHOUSE | South Africa | 1 | $35K | ALPHAMED FORMULATION… | Capsule |
| 3 | THU KHA EAI TRADING CO LTD | Myanmar | 3 | $34K | SURAKSHA PHARMA PVT … | Tablet |
| 4 | GENESIS PHARMACEUTICALS LTD | United Kingdom | 3 | $30K | J B CHEMICALS AND PH… | Tablet |
| 5 | APL SWIFT SERVICES (MALTA) LTD | Malta | 5 | $24K | AUROBINDO PHARMA LTD | Tablet |
| 6 | MASEEH AMIRZAI LTD | Afghanistan | 1 | $20K | LARK LABORATORIES (I… | Tablet |
| 7 | QATAR LIFE FACTORY | Qatar | 1 | $8K | CADILA PHARMACEUTICA… | |
| 8 | M/S.GENERICS AFRICA LTD | Kenya | 1 | $6K | VENOR PHARMA LTD | Tablet |
| 9 | ALSTERN MARINE & OFFSHORE PTE LTD | Singapore | 2 | $3K | AALTOP HEALTHCARE PV… | Tablet |
This report covers 24 2025-Q4 Lorazepam shipments.
TransData Nexus tracks 3.37M+ shipments across all pharmaceuticals since 2020.
→ transdatanexus.com/pharmaceutical/lorazepam
Talk to our trade analyst
Need a custom lorazepam report or a deeper dive into any market? Our team is ready.
WhatsApp: +91 95950 78788 · transdatanexus.com
PHARMA TRADE INTELLIGENCE
Thank you for reading
This report is part of the TransData Nexus Pharma Trade Intelligence series, covering 366 pharmaceutical products exported from India.
Every figure is grounded in real commercial trade records — official customs filings and licensed databases. No surveys, no estimates, no fake data.
Need a custom report?
We can generate intelligence for any pharmaceutical product, any time period, any combination of source and destination countries.
Want deeper analysis?
Our team provides competitive intelligence, market entry strategy, and supply chain due diligence for pharma importers and exporters.
Scan for product page
WhatsApp: +91 95950 78788
Email: info@transdatanexus.com
Web: https://transdatanexus.com/pharmaceutical/lorazepam
© 2026 TransData Nexus. All rights reserved. This report is provided for informational purposes only.
Data sourced from official customs filings and licensed commercial trade databases.
Reproduction without permission is prohibited.
Explore the full Lorazepam product page
Live data, supplier directory, price trends, and trade route analysis